Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bearish
15 minBullish
5 minConsolidating
Daily trend turns up above $4.54
Key levels
Resistance$4.54
Resistance$3.82
Support$1.10
Latest news & SEC filings
AnalystHC Wainwright lowers NeuroSense Therapeutics rating to Neutral
LegalNeuroSense Therapeutics revises when it will submit PrimeC paperwork to Health Canada
LegalNeuroSense delays Health Canada filing for PrimeC to March 2027
AnalystAnalyst Firm Cuts NeuroSense Therapeutics Rating to Neutral
All NRSN news →NeuroSense Therapeutics develops medicines for neurodegenerative conditions and is still in the testing phase, with no approved products. Its main candidate, PrimeC, targets amyotrophic lateral sclerosis (ALS). The company is based in Israel and also works in the United States.
Based on the company's 20-F filed Mar 31, 2026.
Nasdaq · Healthcare
SEPT Low Target
$8.00
SEPT Mid Target
$8.00
SEPT High Target
$8.00
Analyst Consensus
$8.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for NRSN.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$8.00
3
Moat Score
NONE
1/9
Piotroski Score
-90.9
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
18.52%
FCF Growth YoY
24.3%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for NRSN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:56:46 | $1.78 | 1,372 | $$2K | BUY |
| 17:08:17 | $1.76 | 1,000 | $$2K | BUY |
| 15:36:37 | $1.75 | 1,000 | $$2K | SELL |
| 15:33:51 | $1.79 | 1,000 | $$2K | BUY |
| 15:12:44 | $1.89 | 1,000 | $$2K | BUY |
5 dark pool trades shown · $$10K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for NeuroSense Therapeutics Ltd. (NRSN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →NeuroSense Therapeutics Ltd. (NRSN) is at $1.78, down 10.10% (-$0.20) at the Nov 11, 2026 close.
Latest NRSN news — Nov 3, 2026: HC Wainwright lowers NeuroSense Therapeutics rating to Neutral · Nov 3, 2026: NeuroSense Therapeutics revises when it will submit PrimeC paperwork to Health Canada
The average analyst price target for NRSN is $8.00, ranging from $8 to $8, based on 1 analysts. Latest: HC Wainwright & Co. initiates on Sep 3, 2026.
Analyst ratings for NRSN: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
NRSN last reported on Sep 25, 2026: EPS -$2.06 vs -$3.90 expected — a beat of 47.2%.
NRSN does not currently pay a dividend.
Support: $1.10. Resistance: $3.82, $4.54, $6.96.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 3, 2026: HC Wainwright lowers NeuroSense Therapeutics rating to Neutral · Nov 3, 2026: NeuroSense Therapeutics revises when it will submit PrimeC paperwork to Health Canada · Nov 2, 2026: NeuroSense delays Health Canada filing for PrimeC to March 2027